DIRS.INFO The most relevant business & tech news

☆ In new criteria for Alzheimer’s, some see much-needed progress while others fear profit may be driving ‘diagnostic creep’
▼ + stars: | 2024-07-01 | by ( Brenda Goodman | ) edition.cnn.com time to read: +12 min

CNN —With another pricey Alzheimer’s disease treatment expected to receive an approval decision soon, the nonprofit Alzheimer’s Association has published the final version of its new diagnostic criteria for the disease. Together with another protein, tau, which makes fibrous tangles that block the communication of nerve cells, they are considered a hallmark of Alzheimer’s disease. “There’s no evidence for it,” said Dr. George Perry, a neurobiologist and editor of the Journal of Alzheimer’s Disease. Two members of the panel were employees of the Alzheimer’s Association, which also takes funding from pharmaceutical companies. Widera says he hopes that in the next round of guidelines, the Alzheimer’s Association will consider the risks involved.

Persons: There’s, –, donanemab, “, ”, George Perry, Adriane Fugh, Berman, haven’t, Maria C, Carrillo, Alzheimer’s, It’s, Eric Widera, Widera, it’s, Aduhelm, Karl Herrup, Clifford Jack, ” Jack, “ It’s, Niles Franz, ” Franz, Dr, Sanjay Gupta, Franz, ” Widera Organizations: CNN, Alzheimer’s Association, Food and Drug Administration, FDA, Georgetown University, University of California San, American Geriatrics Society, Abbott Labs, University of Pittsburgh School of Medicine, Mayo Clinic, Nature Medicine, federal National Institute, Aging, Alzheimer’s Association International, National Institute, National Institutes of Health, NIA, Alzheimer’s, National Academy of Medicine, CNN Health, Association Locations: University of California San Francisco

☆ Doubts abound about a new Alzheimer’s blood test
▼ + stars: | 2023-10-18 | by ( Judith Graham | ) edition.cnn.com time to read: +10 min

The Quest Diagnostics blood test, AD-Detect, measures elevated levels of amyloid-beta proteins, a signature characteristic of Alzheimer’s. But Alzheimer’s researchers and clinicians aren’t convinced the Quest test is backed by sound scientific research. Though blood tests for Alzheimer’s are likely to become common in the years ahead, the Alzheimer’s Association said it’s premature to offer a test of this kind directly to consumers. Because the science behind blood tests for Alzheimer’s is still developing and because “patients may not really understand the uncertainty of test results,” Edelmayer said, the Alzheimer’s Association “does not endorse the use of the AD-Detect test by consumers.”Quest’s blood test is one of several developments altering the landscape of Alzheimer’s care in the United States. The bottom line: Before taking a test, “older adults need to ask themselves, ‘Why do I want to know this?

Persons: aren’t, Alzheimer’s, Michael Racke, ”, there’s, Suzanne Schindler, St . Louis, That’s, ” Schindler, Racke, Meera Sheffrin, —, Rebecca Edelmayer, ” Edelmayer, Eric Widera, Dr, Sanjay Gupta, Emily Largent, ’ ”, Munro Cullum Organizations: Health, Diagnostics, Alzheimer’s Association, Quest, University of Michigan, International Conference, Washington University School of Medicine, Senior, Stanford Healthcare, The University of Michigan, FDA, National Institute, Aging, University of California, Get CNN, CNN Health, University, Pennsylvania’s Perelman, of Medicine, HIPAA, University of Texas Southwestern Medical Center, Kaiser Health, KFF Locations: U.S, San Diego, St ., United States, San Francisco

☆ Second Alzheimer’s drug to slow disease’s progression may be approved in the US this year
▼ + stars: | 2023-07-17 | by ( Meg Tirrell | ) edition.cnn.com time to read: +12 min

It was shown in May and in fuller Phase 3 clinical trial results released at the Alzheimer’s Association International Conference on Monday to delay the disease’s progression. More than 6 million Americans are estimated to have Alzheimer’s disease, with about 1 million estimated to be in the early symptomatic stages where these drugs have shown benefit. Both Leqembi and donanemab work by clearing buildups of a protein in the brain called amyloid, a hallmark of Alzheimer’s. It’s been a hypothesis that treating Alzheimer’s earlier with amyloid-clearing drugs would yield better results; Skovronsky said the donanemab trial bore that out. “We could look at people who had mild cognitive impairment, MCI, which is the earliest stage, versus mild Alzheimer’s versus moderate Alzheimer’s,” Skovronsky explained.

Persons: Leqembi, Eli Lilly’s donanemab, Lilly, “ Donanemab, Jennifer Manly, Kacie, ”, Dr, Gil Rabinovici, Renaud La Joie, Daniel Skovronsky, “, Skovronsky, ” Skovronsky, It’s, Eric Widera, Sharon Brangman, University of Wisconsin’s Dr, Nathaniel Chin, Donanemab, Lilly hasn’t, Lawrence Honig, Honig, White, Sanjay Gupta, Deters, ” Lilly, it’s “, it’s, there’s, Joe Montminy Organizations: CNN, Alzheimer’s Association, Food and Drug Administration, American Medical Association, Columbia University Irving Medical Center, University of California, MCI, SUNY, University of Wisconsin’s, Leqembi, FDA, donanemab, CNN Health, ” Manly Locations: Los Angeles, “

Search resuls for: "Widera"

3 mentions found